IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2241-2251

  Browne, Tara C ^a   McQuillan, Keith ^a   McManus, Róisín M ^a   O'Reilly, Julie Ann ^a   Mills, Kingston H G ^a   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; PRESENILIN 1; TOLL LIKE RECEPTOR AGONIST;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ISOLATION; COGNITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MICROGLIA; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BRAIN; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID; PRESENILIN-1; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84874225589     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200947     Document Type: Article

References (63)

1. Breitner, J. C. 1996. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47: 401-411.
2. Heneka, M. T., M. P. Kummer, S. Weggen, B. Bulic, G. Multhaup, L. Münter, M. Hüll, T. Pflanzner, and C. U. Pietrzik. 2011. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr. Alzheimer Res. 8: 115-131.
3. Varvel, N. H., K. Bhaskar,M. Z. Kounnas, S. L.Wagner, Y. Yang, B. T. Lamb, and K. Herrup. 2009. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest. 119: 3692-3702.
4. Cagnin, A., D. J. Brooks, A. M. Kennedy, R. N. Gunn, R. Myers, F. E. Turkheimer, T. Jones, and R. B. Banati. 2001. In-vivo measurement of activated microglia in dementia. Lancet 358: 461-467.
5. Okello, A., P. Edison, H. A. Archer, F. E. Turkheimer, J. Kennedy, R. Bullock, Z. Walker, A. Kennedy, N. Fox, M. Rossor, and D. J. Brooks. 2009. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72: 56-62.
6. Liao, Y. F., B. J. Wang, H. T. Cheng, L. H. Kuo, and M. S. Wolfe. 2004. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 279: 49523-49532.
7. Sastre, M., J. Walter, and S. M. Gentleman. 2008. Interactions between APP secretases and inflammatory mediators. J. Neuroinflammation 5: 25.
8. Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
9. Tan, J., T. Town, F. Crawford, T. Mori, A. DelleDonne, R. Crescentini, D. Obregon, R. A. Flavell, and M. J. Mullan. 2002. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5: 1288-1293.
10. Tan, J., T. Town, D. Paris, T. Mori, Z. Suo, F. Crawford, M. P. Mattson, R. A. Flavell, and M. Mullan. 1999. Microglial activation resulting from CD40- CD40L interaction after beta-amyloid stimulation. Science 286: 2352-2355.
11. Town, T., Y. Laouar, C. Pittenger, T. Mori, C. A. Szekely, J. Tan, R. S. Duman, and R. A. Flavell. 2008. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14: 681-687.
12. Colton, C. A., and D. M. Wilcock. 2010. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9: 174-191.
13. Colton, C. A., R. T. Mott, H. Sharpe, Q. Xu, W. E. Van Nostrand, and M. P. Vitek. 2006. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 3: 27.
14. Aloisi, F. 2001. Immune function of microglia. Glia 36: 165-179.
15. Benveniste, E. N., V. T. Nguyen, and G. M. O'Keefe. 2001. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int. 39: 381-391.
16. Kim, W. K., X. Alvarez, J. Fisher, B. Bronfin, S. Westmoreland, J. McLaurin, and K. Williams. 2006. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am. J. Pathol. 168: 822-834.
17. Guillemin, G. J., and B. J. Brew. 2004. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 75: 388-397.
18. Audoy-Rémus, J., J. F. Richard, D. Soulet, H. Zhou, P. Kubes, and L. Vallières. 2008. Rod-Shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2. J. Neurosci. 28: 10187-10199.
19. Serrats, J., J. C. Schiltz, B. García-Bueno, N. van Rooijen, T. M. Reyes, and P. E. Sawchenko. 2010. Dual roles for perivascular macrophages in immune-tobrain signaling. Neuron 65: 94-106.
20. Desai, B. S., A. J. Monahan, P. M. Carvey, and B. Hendey. 2007. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 16: 285-299.
21. Garbuzova-Davis, S., S. Saporta, E. Haller, I. Kolomey, S. P. Bennett, H. Potter, and P. R. Sanberg. 2007. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE 2: e1205.
22. Rosenberg, G. A. 2012. Neurological diseases in relation to the blood-brain barrier. J. Cereb. Blood Flow Metab. 32: 1139-1151.
23. Fletcher, J. M., S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. H. Mills. 2010. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162: 1-11.
24. Murphy, A. C., S. J. Lalor, M. A. Lynch, and K. H. Mills. 2010. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24: 641-651.
25. Togo, T., H. Akiyama, E. Iseki, H. Kondo, K. Ikeda, M. Kato, T. Oda, K. Tsuchiya, and K. Kosaka. 2002. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 124: 83-92.
26. Town, T., J. Tan, R. A. Flavell, and M. Mullan. 2005. T-cells in Alzheimer's disease. Neuromolecular Med. 7: 255-264.
27. Itagaki, S., P. L. McGeer, and H. Akiyama. 1988. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci. Lett. 91: 259-264.
28. Rogers, J., J. Luber-Narod, S. D. Styren, and W. H. Civin. 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging 9: 339-349.
29. Town, T., V. Nikolic, and J. Tan. 2005. The microglial "activation" continuum: from innate to adaptive responses. J. Neuroinflammation 2: 24.
30. Carson, M. J., J. C. Thrash, and B. Walter. 2006. The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin. Neurosci. Res. 6: 237-245.
31. Cao, C., G. W. Arendash, A. Dickson, M. B. Mamcarz, X. Lin, and D. W. Ethell. 2009. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 34: 63-70.
32. McQuillan, K., M. A. Lynch, and K. H. Mills. 2010. Activation of mixed glia by Abeta-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain Behav. Immun. 24: 598-607.
33. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, et al. 1999. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
34. Orgogozo, J. M., S. Gilman, J. F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
35. Tuominen, V. J., S. Ruotoistenmäki, A. Viitanen, M. Jumppanen, and J. Isola. 2010. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12: R56.
36. Jankowsky, J. L., D. J. Fadale, J. Anderson, G. M. Xu, V. Gonzales, N. A. Jenkins, N. G. Copeland, M. K. Lee, L. H. Younkin, S. L. Wagner, et al. 2004. Mutant presenilins specifically elevate the levels of the 42 residue betaamyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13: 159-170.
37. Janus, C., and D. Westaway. 2001. Transgenic mouse models of Alzheimer's disease. Physiol. Behav. 73: 873-886.
38. Hickey, W. F. 1991. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1: 97-105.
39. Hickey, W. F. 2001. Basic principles of immunological surveillance of the normal central nervous system. Glia 36: 118-124.
40. Minagar, A., and J. S. Alexander. 2003. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9: 540-549.
41. Trieb, K., G. Ransmayr, R. Sgonc, H. Lassmann, and B. Grubeck-Loebenstein. 1996. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging 17: 541-547.
42. Loewenbrueck, K. F., J. T. Tigno-Aranjuez, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann. 2010. Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease. Neurobiol. Aging 31: 1732-1742.
43. Janus, C., J. Pearson, J. McLaurin, P. M. Mathews, Y. Jiang, S. D. Schmidt, M. A. Chishti, P. Horne, D. Heslin, J. French, et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
44. Bard, F., C. Cannon, R. Barbour, R. L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6: 916-919.
45. Schenk, D. 2002. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3: 824-828.
46. Ferrer, I., M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa- Jussá. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14: 11-20.
47. Moore, A., L. McCarthy, and K. H. Mills. 1999. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17: 2517-2527.
48. Lyons, A., K. J. Murphy, R. Clarke, and M. A. Lynch. 2011. Atorvastatin prevents age-related and amyloid-b-induced microglial activation by blocking interferon- g release from natural killer cells in the brain. J. Neuroinflammation 8: 27.
49. Meda, L., M. A. Cassatella, G. I. Szendrei, L. Otvos, Jr., P. Baron, M. Villalba, D. Ferrari, and F. Rossi. 1995. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374: 647-650.
50. Chakrabarty, P., C. Ceballos-Diaz, A. Beccard, C. Janus, D. Dickson, T. E. Golde, and P. Das. 2010. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J. Immunol. 184: 5333-5343.
51. O'Connor, R. A., C. T. Prendergast, C. A. Sabatos, C. W. Lau, M. D. Leech, D. C. Wraith, and S. M. Anderton. 2008. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181: 3750-3754.
52. Gallagher, J. J., M. E. Finnegan, B. Grehan, J. Dobson, J. F. Collingwood, and M. A. Lynch. 2012. Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J. Alzheimers Dis. 28: 147-161.
53. Mrak, R. E. 2012. Microglia in Alzheimer brain: a neuropathological perspective. Int. J. Alzheimers Dis. 2012: 165021.
54. Goldgaber, D., H. W. Harris, T. Hla, T. Maciag, R. J. Donnelly, J. S. Jacobsen, M. P. Vitek, and D. C. Gajdusek. 1989. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86: 7606-7610.
55. Yamamoto, M., T. Kiyota, M. Horiba, J. L. Buescher, S. M. Walsh, H. E. Gendelman, and T. Ikezu. 2007. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 170: 680-692.
56. Clarke, R. M., F. O'Connell, A. Lyons, and M. A. Lynch. 2007. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 52: 136-145.
57. Lyons, A., E. J. Downer, S. Crotty, Y. M. Nolan, K. H. Mills, and M. A. Lynch. 2007. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J. Neurosci. 27: 8309-8313.
58. Cao, D., H. Lu, T. L. Lewis, and L. Li. 2007. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282: 36275-36282.
59. Jankowsky, J. L., T. Melnikova, D. J. Fadale, G. M. Xu, H. H. Slunt, V. Gonzales, L. H. Younkin, S. G. Younkin, D. R. Borchelt, and A. V. Savonenko. 2005. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 25: 5217-5224.
60. Westerman, M. A., D. Cooper-Blacketer, A. Mariash, L. Kotilinek, T. Kawarabayashi, L. H. Younkin, G. A. Carlson, S. G. Younkin, and K. H. Ashe. 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22: 1858-1867.
61. Liu, L., T. Tapiola, S. K. Herukka, M. Heikkilä, and H. Tanila. 2003. Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport 14: 163-166.
62. Ethell, D. W., D. Shippy, C. Cao, J. R. Cracchiolo, M. Runfeldt, B. Blake, and G. W. Arendash. 2006. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol. Dis. 23: 351-361.
63. Hauben, E., O. Butovsky, U. Nevo, E. Yoles, G. Moalem, E. Agranov, F. Mor, R. Leibowitz-Amit, E. Pevsner, S. Akselrod, et al. 2000. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20: 6421-6430.